Response of the Insulin-Like Growth Factor (IGF) System to IGF-IR Inhibition and Androgen Deprivation in a Neoadjuvant Prostate Cancer Trial: Effects of Obesity and Androgen Deprivation | Zendy

James P. Dean | Zendy; Cynthia C.T. Sprenger | Zendy; Junxiang Wan | Zendy; Kathleen Haugk | Zendy; William J. Ellis | Zendy; Daniel W. Lin | Zendy; John M. Corman | Zendy; Bruce L. Dalkin | Zendy; Elahe A. Mostaghel | Zendy; Peter S. Nelson | Zendy; Pinchas Cohen | Zendy; Bruce Montgomery | Zendy; Stephen R. Plymate | Zendy

Open Access

Response of the Insulin-Like Growth Factor (IGF) System to IGF-IR Inhibition and Androgen Deprivation in a Neoadjuvant Prostate Cancer Trial: Effects of Obesity and Androgen Deprivation

Author(s) -

James P. Dean,

Cynthia C.T. Sprenger,

Junxiang Wan,

Kathleen Haugk,

William J. Ellis,

Daniel W. Lin,

John M. Corman,

Bruce L. Dalkin,

Elahe A. Mostaghel,

Peter S. Nelson,

Pinchas Cohen,

Bruce Montgomery,

Stephen R. Plymate

Publication year - 2013

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2012-3856

Subject(s) - medicine , prostate cancer , androgen deprivation therapy , bicalutamide , endocrinology , blockade , antiandrogen , oncology , neoadjuvant therapy , cancer , androgen receptor , breast cancer , receptor

Prostate cancer patients at increased risk for relapse after prostatectomy were treated in a neoadjuvant study with androgen deprivation therapy (ADT) in combination with cixutumumab, an inhibitory fully human monoclonal antibody against IGF receptor 1 (IGF-IR).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research